Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low230.41
Day High237.71
Open:232.38
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
The Wall Street subway station is seen on February 03, 2025 in New York City.
the globe and mail

Want safety? Some top-tier U.S. corporate debt trumps Treasuries

Jamie McGeever
Stock Target Advisor
Best Stocks to Withstand Rising Volatility
Best Stocks to Withstand Rising Volatility
Zacks Investment Research
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Motley Fool
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway
Zacks Investment Research
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
Motley Fool
Want Nothing to Do With SpaceX? Buy This Ultra-Low-Cost Dividend Growth ETF in June.
Motley Fool
5 Solid Artificial Intelligence (AI) Stocks That Also Pay Dividends
Tipranks
Analysts’ Top Healthcare Picks: Vera Therapeutics (VERA), Johnson & Johnson (JNJ)
Tipranks
Johnson & Johnson (JNJ) Gets a Buy from Scotiabank
Tipranks
Johnson & Johnson (JNJ) Gets a Buy from Guggenheim
Motley Fool
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
Zacks Investment Research
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Motley Fool
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
Zacks Investment Research
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Motley Fool
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street
Motley Fool
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
Tipranks
Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
Motley Fool
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ
Motley Fool
What the TFSA Fine Print Says About Holding U.S. Stocks
MarketBeat
3 Dividend Kings That Earn Their Crown Every Quarter
MarketBeat.com

Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.